Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New device spots hidden blood clots in real time

NCT ID NCT05301348

Diagnosis Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new device that can find blood clots moving through the bloodstream in people with thromboembolism (blood clots in veins or arteries). About 30 adults with known or high risk of clots will be enrolled. The device uses a special ultrasound technique to detect clots, and researchers will compare its results with standard D-dimer blood tests to see how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Men and women, 18 years old and older. * Evidence of current venous or arterial thromboembolic disease diagnosed by standard of care clinical, radiographic, or laboratory testing or acute ischemic stroke. * Informed consent provided by the subject. Exclusion Criteria * Pulmonary embolus with a need for mechanical ventilation or other ventilator support (may be on oxygen delivered by nasal cannula or mask at an FiO2 of ≤ 0.40) * Acute coronary syndrome (including unstable angina) * Significant cardiac arrhythmia (may have atrial fibrillation controlled with medication) * Intracardiac thrombus * Any embolus or thrombus requiring vascular surgery or interventional radiology to attempt acute embolectomy or thrombectomy * Sickle cell disease with vaso-occlusive crisis * Sepsis or life-threatening infection * Traumatic injury requiring hospitalization (within 30 days prior to enrollment) * Pregnancy or breastfeeding * Severe mental illness * Other conditions deemed by the investigators to put the subject at greater risk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thromboembolic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Thromboembolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Univerisity of Arkansas for Medical Sciences

    RECRUITING

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.